An Open-label Phase II Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations Categorized According to Structural Based Classification
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
The goal of this clinical trial is to explore the efficacy of afatinib in NSCLC harbouring EGFR PACC mutation subtype. The main question it aims to answer is:
Afatinib is active in patients with advanced NSCLC harbouring EGFR PACC mutation subtype.
Participants will undergo screening, follow by treatment if eligible for study participation and then enter follow up phase after study medication has stopped. Patients will take afatinib 40mg daily continuously, until the development of progressive disease or meeting discontinuation criteria. A treatment cycle is defined as 28 days.
详细描述
This is a multi-center, open-label, phase II study of patients with stage IIIb-IV NSCLC harbouring EGFR PACC mutations.
Before taking the study drug, patients will need to undergo baseline assessments to ensure that they are eligible for the study. Then they will enter treatment period, where afatinib 40mg will be administered daily continuously, until the development of progressive disease or meeting discontinuation criteria. A discontinuation visit will be performed if patients stopped study drug for any reason. Thereafter, patients will be placed on Follow Up visit.
Clinical assessment, routine blood tests and routine imaging:
Physical examinations, imaging, and blood tests will be performed during baseline assessment, on the first day of each treatment cycle, after patients have completed the study and when clinically required by the treating physician. Patients will need to visit the doctor's office approximately 1-2 times every 4 weeks when they are receiving active treatment during the course of the study. More frequent visits may be needed as clinically indicated by the treating physician.
Treatment procedure:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytologically confirmed NSCLC.
- •No prior systemic therapy for advanced stage disease.
- •Presence of a PACC mutation (detected either in blood or tumour) as defined by Robichaux et al (24). Compound mutations classified as PACC mutations are permitted (24).
- •The presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (28).
- •Estimated life expectancy of at least 3 months.
- •ECOG performance status 0-
- •Age ≥21 years old.
- •Have adequate organ and hematologic function, as defined by:
- •Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤3.0 x upper limit of normal (ULN) or ≤5 times ULN if related to liver metastases.
- •Total serum bilirubin ≤1.5 × ULN (<3.0 × ULN for patients with Gilbert syndrome)
- •Creatinine clearance >=45mL/min (Cockcroft Gault)
- •Absolute neutrophil count ≥1.5 × 10^9/L
- •Platelet count ≥100 × 10^9/L
- •Hemoglobin ≥ 9.0 g/dL
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •For female patients of childbearing potential, have a negative pregnancy test documented ≤ 14 days prior to start of study medication.
- •Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use a highly effective form of contraception with their sexual partners during the dosing period and for a period of at least 4 months after the end of treatment. Evidence of non-child-bearing potential is fulfilled by one of the following criteria at screening:
- •The post-menopausal period defined as age ≥50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
- •Women <50 years old they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range.
- •Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not a tubal ligation
- •Signed written informed consent.
排除标准
- •Prior EGFR TKI therapy.
- •Prior chemotherapy for Stage IIIB/IV adenocarcinoma of the lung. Neo-/adjuvant chemotherapy, CT-RT or RT is permitted if it has been elapsed for ≥12 months prior to disease progression.
- •Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non melanoma skin cancer or cervical cancer in situ; definitively treated non metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
- •Known leptomeningeal carcinomatosis.
- •Unstable spinal cord compression/brain metastases unless asymptomatic and not requiring steroids for at least 2 weeks prior to the start of study treatment. For patients with brain metastases, gamma knife or stereotactic brain surgery is allowed prior to study treatment.
- •Symptomatic and untreated spinal cord compression.
- •Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: myocardial infarction within 6 months prior to study enrolment; unstable angina within 6 months prior to study enrolment; congestive heart failure within 6 months prior to study enrolment; history of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician; any history of clinically significant ventricular arrhythmia; prolonged QTc.
- •Had a cerebrovascular accident or transient ischemic attack within 6 months prior to enrolment.
- •Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. Minor surgery is allowed.
- •Radiotherapy to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks before the study entry.
- •Inability to swallow oral medication.
- •Refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection that would preclude adequate absorption of afatinib.
- •Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.
- •Have an ongoing or active infection, including, but not limited to, the requirement for intravenous antibiotics.
- •Have a known history of human immunodeficiency virus infection or active hepatitis B or C infection, active tuberculosis.
- •Have a known or suspected hypersensitivity to afatinib or its excipients.
- •Are pregnant, planning a pregnancy, or breastfeeding.
- •Males and females of reproductive potential who are not using an effective method of contraception and females who are pregnant or breastfeeding or have a positive serum pregnancy test prior to study entry.
- •Previous allogeneic bone marrow transplant.
- •Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the study treatment.
研究组 & 干预措施
Afatinib
Afatinib given as monotherapy daily in a 28-days cycle.
干预措施: Afatinib 40 MG (Drug)
结局指标
主要结局
Objective response rate
时间窗: At baseline and every 8 weeks for the first 6 cycles, every 12 weeks from cycle 7 to 12 and every 16 weeks from cycle 13 onwards (each cycle is 28 days)
Defined as best overall response (Complete Response or Partial Response) across all assessment time-points according to RECIST criteria v1.1
次要结局
- Progression free survival(within 4 weeks from starting treatment and every 8 weeks for the first 6 cycles, every 12 weeks from cycle 7 to 12 and every 16 weeks from cycle 13 onwards (each cycle is 28 days))
- Time to treatment failure(48 months)
- Number of participant with treatment related toxicities(48 months)
- Overall survival(48 months)
- Duration of response(every 8 weeks for the first 6 cycles, every 12 weeks from cycle 7 to 12 and every 16 weeks from cycle 13 onwards (each cycle is 28 days))